William Noss Email

Chief Financial Officer . Pulmotect

Current Roles

Employees:
9
Revenue:
$1.4M
About
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body's innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens. Pulmotect’s initial market focus is on the reduction of chronic obstructive pulmonary disease (COPD) exacerbations, which are characterized by an acute worsening of symptoms mostly precipitated by a bacterial or viral infection.
Pulmotect Address
3990 Essex Lane
Houston, TX
United States
Pulmotect Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.